Reduced incidence of CIED infections with peri- and post-operative antibiotic use in CRT-P/D and ICD procedures

Medicine (Baltimore). 2022 Oct 7;101(40):e30944. doi: 10.1097/MD.0000000000030944.

Abstract

Higher cardiac implantable electronic device (CIED) infection incidence has been observed with cardiac resynchronization therapy pacemaker/defibrillator (CRT-P/D) and implantable cardioverter defibrillator (ICD) devices compared to traditional pacemakers with a 1.2% rate reported at 1 year. CIED infection management has high morbidity/mortality. A previous study from this institution demonstrated significantly reduced CIED infection rate when peri/post-operative antibiotics were given for traditional pacemaker procedures. The present study examines CIED infection incidence following peri/post-operative antibiotics during CRT-P/D and ICD procedures. All patients who underwent CRT-P/D and ICD procedures from 1996 to 2015 received IV cephalexin/clindamycin pre- and 8-hours post-procedure followed by 5 days of oral therapy. There were 427 procedures (CRT-P = 146 (34.2%); CRT-D = 142 (33.3%); ICD = 139 (32.6%)). Mean age at time of procedure was 61.6 years. Mean follow-up duration was 4.26 years. CIED infection occurred in 6 patients (ICD = 4, CRT-P = 1, CRT-D = 1), amounting to a rate of 4.96/1000 device-years in total. Times to CIED infection from procedure were: 1.7, 3.5, 6.7, 7.3, 7.9 and 9.2 years. Five out of 6 infections occurred in patients with repeat procedures. This study demonstrates that administration of peri- followed by post-operative antibiotics during CRT-P/D and ICD procedures is associated with a very low rate of CIED infection. This rate of 4.96 infections per 1000 device-years compares favorably to contemporary rates of 8.9 infections per 1000 device-years. Most CIED infections occur late and well-beyond the 1-year follow-up of the Prevention of Arrhythmia Device Infection Trial, the largest trial on this question. This approach should be considered pending a definitive trial.

MeSH terms

  • Anti-Bacterial Agents* / therapeutic use
  • Cardiac Resynchronization Therapy* / adverse effects
  • Cephalexin
  • Clindamycin
  • Clinical Trials as Topic
  • Defibrillators
  • Defibrillators, Implantable* / adverse effects
  • Electronics
  • Heart Diseases / therapy
  • Humans
  • Incidence
  • Middle Aged
  • Prosthesis-Related Infections* / epidemiology
  • Prosthesis-Related Infections* / prevention & control
  • Risk Factors

Substances

  • Anti-Bacterial Agents
  • Clindamycin
  • Cephalexin